BCA cell lines, MDA-MB-231 and MCF-7 were used in the study. They were cultured with Dulbecco Modified Eagle’s Medium (DMEM) (Gibco, Thermo Fisher Scientific, Waltham, MA, USA). These media contained 10% fetal bovine serum (FBS) (Gibco), using penicillin/streptomycin (Gibco) as antibiotics and amphotericin B (Gibco) as an antifungal drug with 5% CO2 and 90% humidity at 37 °C.

Lipofectamine™ 3000 (Invitrogen, Thermo Fisher Scientific) was used to transfect the blank pCDNA™3.1 plasmid (v385–20, Invitrogen) or pCDNA™3.1 PN-plasmid into BCA cell lines. After transfection, the cells were selected by Geneticin™ (Gibco) (up to 1 mg/ml) to create stable cell lines. PN and integrin expressions were tested by reverse transcriptase (RT)-polymerase chain reaction (PCR) using Light Cycler® 480 II system (Roche, Basel, Switzerland) with specific primers (Table 1) [9, 32]. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression was used as an internal control (Table S1). The cycle threshold (Ct) value was used for calculation of expression folding.

Correlation between tissue PN expression and serum PN level in BCA patients (P-value = 0.010)

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.